| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10916019 | Nuclear Medicine and Biology | 2014 | 7 Pages |
Abstract
These studies have demonstrated that compounds based on [18F]flumazenil, but with alterations to allow improved radiosynthesis, can be prepared which have ideal properties and warrant further evaluation as PET agents for the GABAA receptor. In particular, compounds 3 and 5 show very promising profiles with specific binding and in vivo stability comparable to flumazenil.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alexander Jackson, Mark R. Battle, Dennis M. O'Shea, Wai-Fung Chau, Alessandra Gaeta, Samantha L. Brown, Amanda L. Ewan, Clare L. Jones, Paul A. Jones, John L. Woodcraft, Denis R. Bouvet, Benedicte B. Guilbert, William Trigg,